Human Papillomavirus 16/18–Associated Cervical Lesions: Differences by Area-Based Measures of Race and Poverty

ConclusionsDifferences were observed in declines in the proportion of human papillomavirus 16/18 lesions by area-based measures since the introduction of human papillomavirus vaccines, with greater and earlier declines in areas with fewer residents living in poverty and racial minorities. Ongoing human papillomavirus vaccine impact monitoring is necessary to track differences by sociodemographic characteristics.
Source: American Journal of Preventive Medicine - Category: International Medicine & Public Health Source Type: research

Related Links:

ConclusionsProvider recommendations and accurate distribution of information must be increased and targeted to racial/ethnic minority populations in order to bolster the rate of vaccine uptake. To effectively target these communities, multi-level interventions need to be established. Further, research to understand the barriers that may affect unvaccinated adults in the catch-up age range, including males, may be beneficial, as majority of the previous studies focused on either parents of adolescents or women.
Source: Journal of Racial and Ethnic Health Disparities - Category: International Medicine & Public Health Source Type: research
Objective The aim of the study was to compare the rate of high-risk human papillomavirus (HR-HPV) genotypes in vaccinated (Gardasil [quadrivalent]) and unvaccinated cohorts of young women. Materials and Methods This is a retrospective, cross-sectional study, consisting of the comparison of the prevalence of HPV 16, 18, and other HR genotypes in 2183 women younger than 25 years, according to their birth year (born>1994 [mostly vaccinated
Source: Journal of Lower Genital Tract Disease - Category: OBGYN Tags: Cervical Neoplasia Screening and Management Source Type: research
CONCLUSION: In Bhutan, the prevalence of vaccine-targeted HPV types has decreased sharply, providing the first evidence of the effectiveness of a high-coverage national HPV vaccination program in a lower-middle-income country. PRIMARY FUNDING SOURCE: Bill &Melinda Gates Foundation. PMID: 32956600 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - Category: Internal Medicine Authors: Tags: Ann Intern Med Source Type: research
Background: Cervical cancer (CC) is the fourth most commonly diagnosed cancer among women. Ghana is a low-middle- income country with annual diagnosed cases of 3,151 and 2,119 deaths. The high prevalence rate of cervical cancer in Ghana is mainly due to ineffective preventive measures and insufficient knowledge about the disease. Therefore, our objective was to evaluate the level of knowledge and awareness of cervical cancer and attitude toward human papillomavirus and its vaccine among Ghanaians.Methods: This descriptive cross-sectional survey on the awareness of cervical cancer and attitude toward human papillomavirus an...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conditions:   Cervical Intraepithelial Neoplasia;   Cervical Cancer;   Condylomata Acuminata Interventions:   Biological: Nonavalent HPV vaccine;   Biological: Bivalent HPV vaccine Sponsors:   Xiamen University;   Xiamen Innovax Biotech Co., Ltd;   Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Not yet recruiting
Source: - Category: Research Source Type: clinical trials
(Abstracted from Cancer 2020;126:1656–1667)
Source: Obstetrical and Gynecological Survey - Category: OBGYN Tags: GYNECOLOGY: GYNECOLOGIC ONCOLOGY Source Type: research
Source: American Journal of Health Behavior - Category: Psychiatry & Psychology Authors: Source Type: research
Publication date: Available online 25 August 2020Source: BiologicalsAuthor(s): Amin Azimi, Sheida Heidarian, Homa Zamani, Nastaran Taleghani, Mohsen Dehghani, Ehsan Seyedjafari
Source: Biologicals - Category: Biology Source Type: research
Source: Global Public Health - Category: International Medicine & Public Health Authors: Source Type: research
More News: Cervical Cancer Vaccine | Gardasil | Genital Warts | Human Papillomavirus (HPV) | Insurance | International Medicine & Public Health | Vaccines | Women